Consultant Oncoplastic Breast Surgeon Surgical Innovator and National trainer for Association of Breast Surgery.Medico-legal expert,BWFC fan.

Bolton, England
Joined January 2011
Ockenden review: Three hospital bosses were awarded CBEs thetimes.com/article/8a3d5ff… Too often we hear of NHS cover ups by executives, whistle blower harassed and dismissed. Why are lessons from Mid Staffs and others not being learnt.
89
BWFC for the win
1
453
Rick Linforth retweeted
5
86
2,620
Just like to thank the stewards @BWFCST for helping my Dad and I using a wheelchair to access the East stand . First class help and support Well done team .. see you next season.
1
1
73
Rick Linforth retweeted
THE INSPECTOR WHO INSPECTED TOO HONESTLY Dr Shyam Kumar @ukorthopod is an orthopaedic surgeon. A good one. Unblemished record. So the Care Quality Commission (@CareQualityComm) recruited him as a part-time inspector to help hold NHS hospitals to account. He took the job seriously. Too seriously, it turns out. Between 2015 and 2019 he raised concerns about botched hospital inspections, a bullying culture inside the CQC itself, and a surgeon at Morecambe Bay whose hip replacement on an elderly patient left her unable to walk. He asked the CQC to review that surgeon's cases. He was told the trust did not want to do so for reputational reasons. A Royal College of Surgeons review later found problems with 26 out of 46 of that surgeon's operations. The CQC's response to Kumar? They called his concerns fanciful. They dug for dirt on him. Then they sacked him. In September 2022 a Manchester Employment Tribunal ruled he had been unfairly dismissed. The tribunal found his safety disclosures had directly influenced the decision to get rid of him. The judgment noted that CQC officials spent their energy gunning him down rather than focusing on patient safety. He was awarded £23,000 for injury to feelings. Not damages for a ruined career. Not accountability for the officials who ran the smear operation. Just £23,000 and a declaration. The CQC issued a statement saying it had learnt from the case and improved its processes. A decade earlier it said exactly the same thing after the Mid Staffordshire Public Inquiry found it had victimised its own whistleblowers then too. The system that was built to protect patients ran a seven-year campaign against the man raising the alarm. Then it said sorry and carried on. Source: @BBCNews, The Guardian, BMJ, Westminster Confidential (@davidhencke)
42
961
47
1,828
56,611
Anthracyclines rise again
Anthracycline Benefit in High-Risk Breast Cancer 1) Is it time to reconsider the role of Anthracyclines in HR+ HER2- Breast Cancer? New data from the FLEX study reveals a striking 10.7% absolute iDFS benefit for a specific subset of patients. Here is why genomic subtyping matters more than ever. 🧵 #BreastCancer #Oncology #PrecisionMedicine 2) The study focused on patients identified by MammaPrint as High Risk 2 (MP2) and BluePrint as Luminal B . For years, we’ve debated if TC is "enough." In this ultra-high-risk genomic group, the data suggests it might not be. #OncTwitter #FLEXStudy 3) The Results (3-Year iDFS): ✅ ACT (Anthracycline-based): 100% ⚠️ TC (Non-Anthracycline): 89.3% That’s a 10.7% absolute benefit at a median 3.2-year follow-up. In oncology, an absolute gain of this magnitude is a practice-changing signal. 4) Why does this matter? Precision medicine isn't just about de-escalation; it’s about right-escalation. 5) By identifying MP2/Luminal B signatures, we can pinpoint patients who derive maximum benefit from more intensive regimens, ensuring we don't undertreat aggressive biology. While we await longer-term follow-up, the FLEX data reinforces that genomic profiling is essential for tailoring adjuvant therapy. 2026 NCCN Guidelines Now Support This Approach The NCCN now recognizes MammaPrint + BluePrint to identify which HR+/HER2- patients benefit most from anthracycline. Consequently, this marks the first endorsed genomic tool for this decision. Individualized care = Better outcomes. 🎗️ Dr Preetam Jain Medical Oncologist | Director, OncoWorld Cancer Centre #Mumbai #MedOnco Here is the Link : oncologytube.com/mammaprint-… @oncodaily @OncoAlert @TheBreastOnline @ESMO_Open @oncologytube
144
Rick Linforth retweeted
Physical activity reduces all-cause mortality in patients with cancer According to this meta-analysis including 13 RCTs👇 Exercise reduces all-cause mortality in cancer patients by 26%. Not with drugs—through exercise! cancertreatmentreviews.com/a…
9
1
17
965
Rick Linforth retweeted
Did you join us for our Beyond the Scalpel: Planning the Next Chapter webinar? ABS Members can now catch up on demand on the ABS Information Hub. Thanks again to our fantastic speakers Rishi Parmeshwar and Katherine Rogers. Watch here: buff.ly/JpFAYoT
2
134
Rick Linforth retweeted
Pathologic response and prognosis in HER2 + and TNBC . #oncology #medtwitter
2
42
2
102
5,147
Impact of pathologic response and individual prognosis after neoadjuvant treatment in patients with early HER2+ and triple-negative breast cancer - ScienceDirect Great update sciencedirect.com/science/ar…
66
Hot flushes, previous breast cancer ….Veoza now funded by NHS
1
2
1
1
310
Rick Linforth retweeted
📣 Now available as open access on @JCO_ASCO: our analysis on extended endocrine therapy (ET) in premenopausal pts with eBC after 5y of LHRHa. ascopubs.org/doi/10.1200/JCO… Which are the pros and cons of extended ET in this setting? 🤔 A thread 🧵1/ @IEOufficiale @DFCI_BreastOnc
3
18
76
6,387
A missing piece of the endocrine therapy in pre menopausal woman . Don’t forget to add the bisphosphonates for bone health too.
High quality RWD to fill a relevant evidence gap: among 501 young (≤40) pts with node-positive, ER+ breast cancer who had received 5y of OFS, extending ET beyond year 5 was associated with better IBCFS & DRFS. Led by super @ValenzaCarmine! @DFCI_BreastOnc ascopubs.org/doi/10.1200/JCO…
3
177
We’re preparing for the largest #MiamiBreast yet. Make sure not to miss it. Free registration using TARANTINO as promo code here: registration.gotoper.com/mbc…. See you there! 🏝️
1
2
15
2,322
🔥 PALLAS at #SABCS25 Final nail for adjuvant palbociclib ⚰️ 7 year follow up shows no iDFS, DRFS, or OS benefit with adjuvant palbociclib. Post recurrence OS appears shorter, driven by less CDK4/6 reuse and more visceral relapse. 🧪 Bottom line - palbociclib has no role in the adjuvant setting.
🔥 PALLAS at #SABCS25 : Still no role for adjuvant Palbociclib Even with 7 year follow up, PALLAS again shows no gain in iDFS, DRFS, or OS with adjuvant palbociclib. 📉 OS after distant recurrence Shorter in the palbo arm: 22.6 mo vs 27.9 mo for ET alone (HR 1.21). 💡 Why? Palbo patients were less likely to receive CDK4/6i at recurrence and had more visceral relapses, pushing outcomes down. After adjusting for post relapse treatments, the OS gap disappears. 🧪 Key message Adjuvant palbociclib does not improve long term outcomes. Post recurrence CDK4/6 access strongly influences OS signals. #OncoTwitter #MedTwitter #BreastCancer #SABCS25 @OncoAlert @myesmo @esmo_open @ASCO
7
24
2,818
Less is more in the axilla at #SABCS25 💡🫁 #AXSANA shows that in cN1 → ypN0 after NACT, SLNB or TAD matches ALND for 3 year axillary control at ~99 percent 🎯 More surgery did not improve control. Smart de escalation preserves outcomes and quality of life 🌿 #medtwitter #BreastCancer @OncoAlert @SABCSSanAntonio
Less can be more in the axilla at #SABCS25 💡🫁 New #AXSANA data shows that for patients converting from cN1 to ypN0 after NACT, SLNB or TAD matches ALND for 3 year axillary control. Almost zero difference in recurrence. Almost zero reason to overtreat. ➡️ 3 year axillary recurrence free survival SLNB 99.8 percent TAD 98.5 percent ALND 99.2 percent (All confidence intervals overlapping) ➡️ Key message More surgery did not translate into more regional control. Axillary management can be safely de escalated in ycN0 after NACT, provided standards are met. 💭 Why it matters? Avoiding ALND means fewer complications, better QoL, and similar oncologic outcomes. #OncoTwitter #MedTwitter #BreastCancer #SABCS25 @OncoAlert @myesmo @esmo_open @asco
1
15
1
44
3,836